Platform – Talk Bio

Relation and Deerfield form NewCos to develop drugs from AI-discovered targets

1 day ago talkbio0Tagged AI drug discovery, Bone Diseases, Deerfield Management, Drug Delivery Systems, Immunology, Lab-in-the-Loop, Metabolic Diseases, newco, Platform, Relative (related person), royalties, strategic collaboration

Relation; Deerfield Management; strategic collaboration; NewCo; AI drug discovery; Lab-in-the-Loop platform; novel therapeutics; immunology; metabolic disease; bone disease; drug targets; royalties

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

3 weeks ago talkbio0Tagged Antisense Oligonucleotides, Antistreptolysin O, CAMP4, Collaboration, gene upregulation, Kidney Diseases, LRPAP1 gene, milestone payments, Neurodegenerative Disorders, Platform, regulatory RNA, RNA therapeutics, royalties, SmithKline Beecham

GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties

MediKarma Scales Its Clinical And Commercial Acumen With Appointment Of Dr. Scott Howell As Chief Clinical Officer And Angela Breton As Chief Revenue Officer

2 months ago talkbio0Tagged AI-driven, Angela Breton, Chief Clinical Officer, Chief Revenue Officer, MediKarma, Patient data, Platform, proactive care, Scott Howell

MediKarma; Scott Howell; Angela Breton; Chief Clinical Officer; Chief Revenue Officer; AI-driven platform; patient data; proactive care

Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Clinical trial failure, GalNAc, Korro Bio, KRRO-110, layoffs, Nordisk, Partnership, Platform, RNA Editing

Korro Bio; KRRO-110; Alpha-1 Antitrypsin Deficiency (AATD); RNA editing; clinical trial failure; layoffs; Novo Nordisk partnership; GalNAc platform; biotech strategy shift

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

2 months ago talkbio0Tagged 2026, Acquisition, AOC, Avidity Biosciences, Closed, Muscular Dystrophy, Duchenne, Muscular Dystrophy, Facioscapulohumeral, MYOTONIC DYSTROPHY 1, Neuromuscular Diseases, Novartis, Platform, RNA therapeutics, SpinCo ', xRNA

Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

3 months ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

3 months ago talkbio0Tagged Antibodies, Biosciences, Cartography, CBI-1214, Cervical Atlas, Colorectal Carcinoma, Neoplasms, Pfizer Ventures, Platform, Series B funding, summit, T-Cell engager

Cartography Biosciences; Series B Funding; Pfizer Ventures; CBI-1214; T-cell engager; colorectal cancer (CRC); ATLAS platform; SUMMIT platform; antibody therapeutics; oncology

May the (Power of the) Pool be with you: Accelerating time from DNA to GMP – STI-based CLD Platform

7 months ago talkbio0Tagged Biopharma, cell line development, DNA, Endpoints, Guanosine Monophosphate, Platform, STI-based, time acceleration, webinar

DNA to GMP; STI-based CLD Platform; bioprocessing; Endpoints News; webinar; cell line development; biopharma; time acceleration